CD160 and neoplasm: Liu et al. (Liu et al., 2020) observed that tumor-infiltrating CD8+ T cells were significantly enriched with the CD160+ subset in pancreatic cancer patients, and patients with higher frequencies of tumor CD160+CD8+ T cells presented lower survival.